药品注册申请号:020103
申请类型:NDA (新药申请)
申请人:SANDOZ
申请人全名:SANDOZ INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 ZOFRAN ONDANSETRON HYDROCHLORIDE TABLET;ORAL EQ 4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Yes No None 1992/12/31 1992/12/31 Discontinued
002 ZOFRAN ONDANSETRON HYDROCHLORIDE TABLET;ORAL EQ 8MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Yes No None 1992/12/31 Discontinued
003 ZOFRAN ONDANSETRON HYDROCHLORIDE TABLET;ORAL EQ 24MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Yes No None 1999/08/27 Discontinued
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2021/10/20 SUPPL-38(补充) Approval Labeling STANDARD
2021/04/29 SUPPL-37(补充) Approval Labeling STANDARD
2017/10/05 SUPPL-36(补充) Approval Labeling STANDARD
2016/11/09 SUPPL-35(补充) Approval Labeling STANDARD
2016/09/28 SUPPL-33(补充) Approval Labeling STANDARD
2014/09/18 SUPPL-34(补充) Approval Labeling 901 REQUIRED
2013/12/10 SUPPL-31(补充) Approval Labeling STANDARD
2011/09/14 SUPPL-30(补充) Approval Labeling STANDARD
2010/09/22 SUPPL-29(补充) Approval Labeling UNKNOWN
2006/08/22 SUPPL-27(补充) Approval Labeling STANDARD
2005/12/27 SUPPL-25(补充) Approval Labeling STANDARD
2005/02/18 SUPPL-24(补充) Approval Manufacturing (CMC) PRIORITY
2004/11/24 SUPPL-23(补充) Approval Labeling STANDARD
2003/01/31 SUPPL-21(补充) Approval Labeling STANDARD
2001/10/24 SUPPL-20(补充) Approval Manufacturing (CMC) PRIORITY
2001/10/24 SUPPL-19(补充) Approval Manufacturing (CMC) PRIORITY
2000/12/13 SUPPL-18(补充) Approval Labeling STANDARD
2000/04/11 SUPPL-17(补充) Approval Labeling STANDARD
1999/08/27 SUPPL-16(补充) Approval Manufacturing (CMC) PRIORITY
1999/08/27 SUPPL-15(补充) Approval Efficacy STANDARD
1997/04/15 SUPPL-13(补充) Approval Labeling STANDARD
1995/11/16 SUPPL-11(补充) Approval Labeling STANDARD
1995/05/17 SUPPL-10(补充) Approval Manufacturing (CMC) PRIORITY
1995/04/19 SUPPL-5(补充) Approval Efficacy STANDARD
1995/04/10 SUPPL-8(补充) Approval Efficacy UNKNOWN
1995/02/14 SUPPL-9(补充) Approval Manufacturing (CMC) PRIORITY
1994/09/26 SUPPL-4(补充) Approval Efficacy PRIORITY
1994/04/27 SUPPL-7(补充) Approval Labeling STANDARD
1994/04/15 SUPPL-6(补充) Approval Manufacturing (CMC) PRIORITY
1994/04/04 SUPPL-3(补充) Approval Labeling STANDARD
1993/09/28 SUPPL-2(补充) Approval Manufacturing (CMC) PRIORITY
1993/02/22 SUPPL-1(补充) Approval Labeling STANDARD
1992/12/31 ORIG-1(原始申请) Approval Type 3 - New Dosage Form PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
001 4753789*PED 2006/12/24 PDF格式**本条是由Drugfuture回溯的历史信息**
5344658 2011/09/06 PDF格式**本条是由Drugfuture回溯的历史信息**
5344658*PED 2012/03/06 PDF格式**本条是由Drugfuture回溯的历史信息**
002 4753789*PED 2006/12/24 PDF格式**本条是由Drugfuture回溯的历史信息**
5344658 2011/09/06 PDF格式**本条是由Drugfuture回溯的历史信息**
5344658*PED 2012/03/06 PDF格式**本条是由Drugfuture回溯的历史信息**
003 4753789*PED 2006/12/24 PDF格式**本条是由Drugfuture回溯的历史信息**
5344658 2011/09/06 PDF格式**本条是由Drugfuture回溯的历史信息**
5344658*PED 2012/03/06 PDF格式**本条是由Drugfuture回溯的历史信息**
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
本品无治疗等效药品
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database